| 孙 柳,杨长亮,阳 光,吴雄英,张 峰.孟鲁司特钠对过敏性鼻炎患者血清IL-5和IL-10水平的影响及安全性分析[J].,2017,17(32):6304-6307 |
| 孟鲁司特钠对过敏性鼻炎患者血清IL-5和IL-10水平的影响及安全性分析 |
| Effects of Montelukast on Serum Levels of IL-5 and IL-10 of Patients with Allergic Rhinitis and Safety Analysis |
| 投稿时间：2017-06-05 修订日期：2017-06-25 |
| DOI：10.13241/j.cnki.pmb.2017.32.022 |
| 中文关键词: 过敏性鼻炎 孟鲁斯特钠 炎性因子 症状积分 安全性 |
| 英文关键词: Allergic rhinitis Montelukast Inflammatory cytokines Symptoms integral Safety |
| 基金项目:湖北省自然科学基金项目(2013CKB006) |
|
| 摘要点击次数: 206 |
| 全文下载次数: 175 |
| 中文摘要: |
| 摘要 目的：分析孟鲁司特钠对过敏性鼻炎患者血清白细胞介素-5（IL-5）及白细胞介素-10（IL-10）水平的影响及安全性。方法：选择我院2015年10月~2016年10月收治的106例过敏性鼻炎患者，按不同治疗方式分作对照组与研究组，每组53例。对照组选用氯雷他定片治疗；研究组在对照组基础上加以孟鲁司特钠治疗。观察并比较两组患者的临床疗效、治疗前后血清IL-5及IL-10水平变化、症状及体征积分及不良反应发生情况。结果：研究组总有效率（94.33%）高于对照组 （79.24%）（P<0.05）。治疗后，两组血清IL-5，症状及体征积分均显著下降，研究组下降更明显，两组血清IL-10均有显著上升，研究组上升更明显，差异均有统计学意义（P<0.05）。两组不良反应发生情况比较，差异无统计学意义（P>0.05）。结论：孟鲁司特钠能够调节过敏性鼻炎患者血清炎症因子水平，降低症状积分，且安全性较高。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the clinical effects of montelukast on the serum levels of IL-5 and IL-10 of patients with allergic rhinitis and and drug safety. Methods: 106 cases with allergic rhinitis who were treated in our hospital from October 2015 to October 2016 were selected and according to the different treatment methods, the patients were divided into the control group and the research group with 53 cases in each group. The patients in the control group were treated with loratadine tablets, while the patients in the research group were treated with montelukast besides of the control group. Then the clinical efficacy, the serum levels of IL-5 and IL-10, the symptoms and the occurrence of adverse reactions between two groups were observed and compared. Results: The total effective rate of the research group was 94.33%, which was higher than 79.24% of the control group (P<0.05). After treatment, the serum levels of IL-5 and the symptoms and signs points of two groups significantly decreased, and the research group were lower than those of the control group (P<0.05); After treatment, the serum levels of IL-10 in the two groups increased, and the research group was higher than that of the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference about the incidence of adverse reactions between two group (P>0.05). Conclusion: Montelukast has better effect on the treatment of allergic rhinitis, which can regulate the serum levels of inflammation factors, reduce the symptom scores with higher safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
